{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-044855","form_type":"8-K","ticker":"PURE","cik":"0001006028","company_name":"PURE BIOSCIENCE, INC.","filed_at":"2023-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.818206+00:00","generated_at":"2026-06-07T12:28:09.622468+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PURE Bioscience Q1 revenue rises 54% to $718K; net loss narrows to $735K","bullets":["Net product sales of $718K for Q1 FY2024, up $251K from $467K in Q1 FY2023.","Net loss improved to $735K from $993K year-over-year; EPS unchanged at ($0.01).","Excluding share-based compensation, net loss was $655K vs $909K.","CEO cites sales initiatives paying off; VP of Sales highlights competitive advantage in food safety.","Business update stresses customer focus, IoT/SaaS innovation, and 100 years of combined staff experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-044855","json":"https://secwatch.observer/filing/0001493152-23-044855.json","markdown":"https://secwatch.observer/filing/0001493152-23-044855.md","text":"https://secwatch.observer/filing/0001493152-23-044855.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006028/000149315223044855/0001493152-23-044855-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006028/000149315223044855/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T12:28:09.622468+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}